Leap Therapeutics, Inc. acquires and develops therapies for the treatment of cancer. DKN-01,a monoclonal antibody that inhibits Dickkopf-related protein 1, is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers.
